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Background: Concomitant primary cutaneous melanoma in monozygotic twins has been reported in only two
pairs but in neither of them genetic analysis was performed. Two high-penetrance susceptibility genes, CDKN2A
and CDK4 and one low-penetrance gene, MC1R, are well-defined genetic risk factors for melanoma. MITF has been
recently identified as a novel intermediate risk melanoma-predisposing gene.
Case presentation: We describe the extraordinary occurrence of a primary cutaneous invasive melanoma in two
44-year-old identical, female twins, on the same body site within 30 days of each other and report for the first time
the genetic analysis of melanoma susceptibility genes in both twins. Data on characteristics of the twins were
collected through a standardized questionnaire and skin examination. Exons 1α, 1β, 2 and 3 of CDKN2A, exon 2 of
CDK4, the entire open reading frame of MC1R and the recently described MITF c.952 G>A (p.Glu318Lys) variant
were investigated by direct sequencing. Sequencing analysis of the high-penetrance susceptibility genes showed
no changes in CDKN2A and in exon 2 of the CDK4 gene. Both patients were heterozygous for the same CDKN2A
UTR c.*29C >G variant. Interestingly, the same two heterozygous variants of the MC1R were identified in both twins:
the c.451C > T (p.Arg151Cys) and the c.456C >A (p.Tyr152*) variants. Neither patient showed the c.952 G>A
(p.Glu318Lys) substitution in the MITF gene.
Conclusions: Identification of two high-risk MC1R variants in our identical twins in the absence of CDKN2A and
CDK4 mutations highlights the contribution of low penetrance genes, such as MC1R, in melanoma susceptibility.
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Genetic, phenotypic and environmental factors are
known to affect melanoma risk. Two high-penetrance
susceptibility genes, CDKN2A (cyclin-dependent kinase
inhibitor 2A, MIM 600160) and CDK4 (cyclin-dependent
kinase 4, MIM 123829) and one low-penetrance gene,
MC1R (melanocortin-1 receptor, MIM 155555), have
been identified so far as genetic risk factors for melanoma
[1-3]. CDKN2A is the major melanoma susceptibility
gene, mutated in approximately 40 % of melanoma-
prone families with at least three affected members.
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reproduction in any medium, provided the ora limited number of melanoma families worldwide. Allelic
variants in the MC1R gene, important in the pigmenta-
tion process, have been associated with increased melan-
oma risk, with the strongest effect observed for red
hair color (RHC) variants (p.ArgR151Cys, p.Arg160Trp,
p.Asp294His). Recently, whole genome sequencing lead
to the identification of MITF (microphtalmia-associated
transcription factor, MIM 156845) as a novel melanoma-
predisposing gene with the p.Glu318Lys variant defined
as an intermediate risk variant [4].
We describe the extraordinary occurrence of a primary
cutaneous invasive melanoma in two 44-year-old female,
identical twins, on the same body site within 30 days of
each other and report for the first time genetic analysis
of melanoma susceptibility genes in both twins.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Phenotypic appearance of the twins and of their melanomas and identified germline MC1R variants. (A) Phenotypic features of
twin-1 (left) and twin-2 (right); (B) Clinical image of twin-1’s melanoma located on the right anterior upper trunk; (C) Clinical image of twin-2’s
melanoma excised from the right anterior lower trunk; (D) Heterozygous substitutions at codons 151 and 152 of the MC1R gene (NCBI accession
NM_002386.3) identified in both twins.
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A pair of female monozygotic twins who were included
in a surveillance program at our Pigmented Lesion
Clinic for the presence of multiple atypical nevi and at
risk phenotype (Figure 1A) had been lost of follow-up
over the last two years due to the 2009 earthquake in
L’Aquila. Twin-1 presented with a one-year history of an
irregularly-shaped, pink, light to dark brown, slowly
growing plaque with irregular borders located on the
right anterior upper trunk (Figure 1B). Thirty days later,
twin-2 was examined for an asymmetrical, pink to light
brown melanocytic lesion which had developed approxi-
mately 4 months earlier on the right anterior lower
trunk (Figure 1C). Both patients referred a pre- existing
pigmented lesion which changed in color and size.
Dermatoscopic analysis showed irregular dots/globules,
irregular streaks and a polymorphic vascular pattern in
both cases. Histopathological examination showed a
superficial spreading melanoma (SSM), 0.65 mm in Bre-
slow thickness in twin-1 and a 0.33 mm thick SSM in
twin-2. Both patients were skin type 1 (red hair, green
eyes, fair-skinned, many ephelides) and were affected by
the atypical mole syndrome with a total of 508 melano-
cytic nevi in twin-1 and of 375 nevi in twin-2. They
reported numerous episodes of sunburns during child-
hood/adolescence, but different acute sun exposure
habits in the adult life with longer recreational sun
exposure (6 hours/day/4 weeks/year) for twin-1 than
twin-2 (2 hours/day/2 weeks/year). They had neitherpersonal nor family history of melanoma and twin-1 had
three basal cell carcinomas excised.
Genetic analysis
Genomic DNA was isolated from whole blood of both
patients using QIAampW DNA Blood kit (Qiagen, Hilden,
Germany). Exons 1α, 1β, 2 and 3, including the exon-
intron boundaries of CDKN2A (NCBI accession
NM_000077.3), exon 2 of CDK4 (NCBI accession
NM_000075.3) and the entire open reading frame of
MC1R (NCBI accession NM_002386.3) were amplified
using PCR and directly sequenced on ABI PrismW 310
Genetic Analyzer (Applied Biosystems, Foster City, CA) as
described previously [5,6]. The recently described MITF
c.952 G>A (p.Glu318Lys) variant (NCBI accession
NM_000248.3) was screened by direct sequencing of a
PCR-amplified 589 amplicon using the following primers:
forward, 5'-TACATTCCCTCTGGTATTGT-3'; reverse,
5'-AGCAGTTTGTGCGAATGCA-3'. Primers for PCR
amplification were designed from the MITF genomic nu-
cleotide sequence (NCBI accession NG_011631.1) and
were the followings: forward, 5'-TACATTCCCTCTGG-
TATT GT-3'; reverse 5'-AGCAGTTTGTGCGAATGCA-
3'. An amplicon of 589 bp was obtained by standard PCR
using 1.25 U of AmpliTaq GoldW 360 (Applied Biosys-
tems) in a 50-μl volume, containing the 1X reaction buffer
provided by the manufacturer, 1.6 mM of MgCl2, 200 μM
of each deoxynucleoside triphosphate, 0.2 μM of each
primer and 100 ng genomic DNA template. Five per cent
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PCR amplification conditions were as follows: 95°C for
7 min, 35 cycles of 94°C for 1 min, 52.2°C for 1 min, and
72°C for 1 min, followed by a final extension step at 72°C
for 7 min. Written informed consent was obtained from
our patients under an Institutional Review Board-
approved protocol.
Sequencing analysis showed no changes in the coding
region and in the 5’UTR region of CDKN2A, although
both patients were heterozygous for the same UTR
c.*29C >G variant. No mutations were detected in exon
2 of the CDK4 gene. Interestingly, sequencing of the
MC1R identified the same two heterozygous variants in
both twins: the c.451C >T (p.Arg151Cys) and the
c.456C >A (p.Tyr152*) variants (Figure 1D). Neither
patient showed the c.1075 G>A (p.Glu318Lys) substitu-
tion in the MITF gene.
Conclusions
The occurrence of melanoma concordant for site and
age of onset in monozygotic twins has been reported in
only two pairs but in neither of them genetic analysis
was performed. St-Arneault et al. [7] described two
identical male twins (from a set of triplets) who devel-
oped melanoma at age 53, at the same site and within a
time frame of 2 months, while the fraternal triplet
showed no evidence of tumour. More recently, Rao
et al. [8] reported two 71-year-old, identical female
twins, diagnosed with melanoma at the same time
(within 10 days of each other) and location (right calf ).
Our patients were skin type 1 as the latter pair but they
were younger than both pairs.
Studies in twin pairs are of great interest to estimate
the relative effect of genetic and environmental influ-
ences on melanoma development. In a recent large
population-based study of Australian twins, genetic
influences were shown to be a significant source of vari-
ation in liability to melanoma with identical twins being
more than four times more likely to be affected with
melanoma if they had an affected co-twin than non-
identical twins [9].
MC1R variants have been associated with a 1.2 to 2.4-
fold increased risk of melanoma with an additive effect
for multiple variants [10-12]. A double variation in
the MC1R gene, the c.451C >T (p.Arg151Cys) and the
c.456C >A (p.Tyr152*), was detected in our twins. The
p.Arg151Cys has been shown to confer the highest
melanoma risk with summary estimates ranging from
1.78 (95%CI 1.45–2.20) to 1.93 (95%CI 1.54–2.41) in
two recent meta-analyses [10,11]. We previously
reported a significant association of the p.Arg151Cys
allele with melanoma risk in a population from central
Italy, with an OR of 2.94 (95%CI, 1.04–8.31) [6]. In func-
tional studies, the p.Arg151Cys mutant receptor showeda reduced cell surface expression with intracellular
retention and a corresponding impairment in cAMP
coupling [13]. The nonsense p.Tyr152* is a rare RHC
variant associated with a severe functional impairment
of the MC1R due to the lack of the last four transmem-
brane fragments [14,15]. Interestingly, MC1R-associated
melanoma risk has been shown to increase with the
number of variants in the genotype supporting the
MC1R-associated susceptibility in our patients carrying
two nonfunctional MC1R variants. Finally, carriers of
MC1R RHC variants have been recently suggested to de-
velop melanomas lacking significant pigmentation [16,17]
as also observed in the hypomelanotic melanomas of
our twins.
In addition to the well-defined association of MC1R
with melanoma, other low-penetrance melanoma risk
alleles have been described in genes related to pigmenta-
tion, nevus count, immune responses, DNA repair, me-
tabolism and the vitamin D receptor [12]. In this regard,
we cannot rule out the possible involvement of other
low-penetrance melanoma susceptibility alleles in our
twins since they were not genotyped in our patients.
The concordance for cutaneous melanoma as well as
the congruence for its location and identity of the age of
onset in monozygotic twins support the role of genetic
rather than environmental factors in the development of
melanoma. Detection of two high-risk MC1R variants in
our identical twins in the absence of CDKN2A and
CDK4 mutations highlights the contribution of low
penetrance genes, such as MC1R, in melanoma suscepti-
bility, although additional known or as yet unknown
genetic risk factors might be involved.
Consent
Written informed consent was obtained from both
patients for publication of this case report and any
accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
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